JP6615200B2 - Composition for prevention and treatment of benign prostatic hyperplasia containing carrot seed oil, and formulation obtained by formulating the composition - Google Patents

Composition for prevention and treatment of benign prostatic hyperplasia containing carrot seed oil, and formulation obtained by formulating the composition Download PDF

Info

Publication number
JP6615200B2
JP6615200B2 JP2017523344A JP2017523344A JP6615200B2 JP 6615200 B2 JP6615200 B2 JP 6615200B2 JP 2017523344 A JP2017523344 A JP 2017523344A JP 2017523344 A JP2017523344 A JP 2017523344A JP 6615200 B2 JP6615200 B2 JP 6615200B2
Authority
JP
Japan
Prior art keywords
composition
seed oil
carrot seed
carrot
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017523344A
Other languages
Japanese (ja)
Other versions
JP2018500285A (en
Inventor
ス ファン キム
チャン ウン パク
スン ミン キム
ワン ギ キム
サン ジュン リ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Publication of JP2018500285A publication Critical patent/JP2018500285A/en
Application granted granted Critical
Publication of JP6615200B2 publication Critical patent/JP6615200B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/20Natural extracts
    • A23V2250/21Plant extracts
    • A23V2250/2124Ginseng

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Description

本発明はニンジン種子油を含有して男性の前立腺肥大症の予防と治療に効果的な組成物に関する。   The present invention relates to a composition containing carrot seed oil and effective in preventing and treating male prostatic hypertrophy.

高麗ニンジン(高麗人参)(Panax ginseng C.A. Meyer)は五加皮科ニンジン属に属する植物で、韓国、中国、日本等の地域で2,000年前から用いられて来た生薬で、経験的に疾病を予防し、寿命を延長させる目的で用いられてきた。今まで知られている高麗ニンジンの効能及び効果は中枢神経系に対する作用、抗発癌作用、抗癌活性作用、免疫機能調節作用、抗糖尿作用、肝機能亢進効能、心血管障害改善、抗動脈硬化作用、血圧調節作用、更年期障害改善、骨粗しょう症に及ぼす効果、抗ストレス作用、抗疲労作用、抗酸化活性、老化抑制効能などが知られている(最新高麗人参「成分及び効能編」、韓国高麗人参煙草研究院、56−112、1996)。   Panax ginseng CA Meyer is a plant belonging to the genus Carrot, a herbal medicine that has been used in 2,000 years ago in Korea, China, Japan and other regions. It has been used to prevent disease and extend lifespan. The effects and effects of ginseng known so far are the action on the central nervous system, anti-carcinogenic action, anti-cancer activity action, immune function regulating action, anti-diabetic action, liver function enhancement effect, cardiovascular disorder improvement, anti-arteriosclerosis Known for its effects on blood pressure, blood pressure regulation, menopause, osteoporosis, anti-stress, anti-fatigue, anti-oxidation, anti-aging effects, etc. Ginseng Tobacco Research Institute, 56-112, 1996).

一方、ニンジン種子は約15〜26%のオイルを含有しており(Beveridgeなど2002;Matsumotoなど1986)、主要な脂肪酸成分として一価の不飽和脂肪酸であるオレイン酸(C18:1)の含有量が高くてオリーブオイルと類似する脂肪酸組成を有することが分かっている。   On the other hand, carrot seeds contain about 15 to 26% oil (Beveridge et al. 2002; Matsumoto et al. 1986), and the content of oleic acid (C18: 1), which is a monovalent unsaturated fatty acid, as the main fatty acid component. Is high and has a fatty acid composition similar to olive oil.

また、ニンジン種子油に血中コレステロールを減少させる効能があるスクアレン、オキシドスクアレン、カンペステロール、スチグマステロール、シトステロールなどのような多様なフィトステロールが存在することが明らかになって、機能性原料としてニンジン種子油の利用可能性が浮上している。その他、現在まで行われたニンジン種子に関する研究では、ニンジン種子とニンジン根のジンセノサイド組成に関する研究(Huなど2008)、ニンジン種子と果肉のサポニン組成に関する研究、山地別ニンジン種子油の組成と酸化安定性比較研究、高圧殺菌処理によるニンジン種子の抗酸化効果など、主にニンジン種子のジンセノサイド組成とニンジン種子油の組成に関する研究が報告されている。このように、ニンジン種子油の食品学的価値は持続的に研究されているが、ニンジン根及び実に対する研究に比べてその成果は些細なことが現実である。   In addition, it has become clear that carrot seed oil contains various phytosterols such as squalene, oxidosqualene, campesterol, stigmasterol, sitosterol, etc., which have the effect of reducing blood cholesterol, and carrots as a functional ingredient. The availability of seed oil is emerging. Other studies on carrot seeds to date include studies on ginsenoside composition of carrot seeds and carrot roots (Hu et al. 2008), research on saponin composition of carrot seeds and pulp, composition and oxidation stability of carrot seed oil by mountain Studies on the ginsenoside composition of carrot seeds and the composition of carrot seed oil have been reported, including comparative studies and antioxidant effects of carrot seeds by high-pressure sterilization. In this way, the foodological value of carrot seed oil has been continuously researched, but the results are insignificant compared to research on carrot roots and fruits.

そこで、本発明者らはニンジン種子油の人体健康に対する新規用途に対して研究した結果、ニンジン種子油が男性の前立腺肥大症の緩和に効果的に作用することを見出し、本発明の完成に至った。   Therefore, as a result of researches on the novel use of carrot seed oil for human health, the present inventors have found that carrot seed oil effectively acts to alleviate male benign prostatic hyperplasia, leading to the completion of the present invention. It was.

従って、本発明は、ニンジン種子油を含有して男性の前立腺肥大症予防と治療に効果的な組成物を提供することを目的とする。   Accordingly, an object of the present invention is to provide a composition containing carrot seed oil and effective in preventing and treating male prostatic hypertrophy.

上記した目的を達するために、本発明は、ニンジン種子油を有効成分として含有する男性の前立腺肥大症の予防及び治療用の組成物を提供する。   In order to achieve the above-mentioned object, the present invention provides a composition for preventing and treating male prostatic hypertrophy, which contains carrot seed oil as an active ingredient.

本発明の組成物は男性の前立腺肥大症症状を緩和させ、これを予防するのに効果的であるだけでなく、疲労回復、体重減少、コレステロール及び中性脂肪改善などの人体健康増進に役に立ち、それにより、食品及び医薬分野で多様に活用されることができる。   The composition of the present invention is effective not only to alleviate and prevent symptoms of prostatic hypertrophy in men, but also to promote human health such as fatigue recovery, weight loss, cholesterol and neutral fat improvement, Thereby, it can be used in various ways in the food and pharmaceutical fields.

ニンジン種子油を加工する段階を示すダイヤグラムである。It is a diagram which shows the step which processes carrot seed oil.

本発明はニンジン種子油を含有して、男性の前立腺肥大症症状の予防と治療に効果的に作用することができる組成物に関する。   The present invention relates to a composition containing carrot seed oil and capable of effectively acting in the prevention and treatment of male prostatic hypertrophy symptoms.

本発明で用いるニンジン種子油は、その加工方法は特に限定されないが、例えば図1に示した加工段階によって製造されることができる。具体的には、次のような工程を含む。   The processing method of the carrot seed oil used in the present invention is not particularly limited. For example, the carrot seed oil can be manufactured by the processing steps shown in FIG. Specifically, the following steps are included.

(a)ニンジン実からニンジン種子を得る段階と、
(b)上記段階で得たニンジン種子を搾油してニンジン種子油を得る段階。
(A) obtaining carrot seeds from carrot fruit;
(B) A step of obtaining carrot seed oil by extracting the carrot seed obtained in the above step.

上記(a)段階でニンジン種子は芽が出たり出ないものを全部含有し、生ニンジンの種子であってもよく、日光乾燥または熱風乾燥を通じて乾燥したものであってもよい。   In the step (a), the carrot seeds contain everything that does not sprout or emerge, and may be raw carrot seeds, or may be dried through sunlight drying or hot air drying.

本発明でニンジン種子を搾油する方法は特に限定されず、公知された様々な方法を利用することができる。   The method for extracting carrot seeds in the present invention is not particularly limited, and various known methods can be used.

本発明による一実施形態で、本発明のニンジン種子油はニンジン種子を搾油機に入れて圧搾して有用成分を抽出する、ニンジン種子を圧搾する圧搾法によって得られることができる。この時、食品用搾油機であれば制限されることなく使用可能であり、搾油時間は3〜20分であることが好ましく、搾油は普通常温で実施する。   In one embodiment according to the present invention, the carrot seed oil of the present invention can be obtained by a squeezing method of squeezing carrot seeds by extracting carrot seeds into an oil press and extracting useful components. At this time, if it is a food oil press, it can be used without limitation, and the oil extraction time is preferably 3 to 20 minutes, and oil extraction is usually carried out at room temperature.

本発明による他の実施形態で、ニンジン種子油は超臨界抽出法(Supercritical Water Extraction)で抽出されることができる。超臨界抽出は臨界点を超えた状態の超臨界流体を利用することで、用いる超臨界流体の種類が特に限定されるのではないが、ペンタン、二酸化炭素などが用いられることができ、特に二酸化炭素が用いられることができる。また、用いる溶媒の種類は特に限定されるものではないが、特に、本発明では溶媒として酒精または精製水を用いることができる。   In another embodiment according to the present invention, carrot seed oil can be extracted by Supercritical Water Extraction. Supercritical extraction uses a supercritical fluid in a state exceeding the critical point, and the type of supercritical fluid to be used is not particularly limited. However, pentane, carbon dioxide, etc. can be used, particularly dioxide. Carbon can be used. Moreover, the kind of solvent to be used is not particularly limited. In particular, in the present invention, alcohol or purified water can be used as a solvent.

本発明による他の実施形態で、ニンジン種子油は亜臨界抽出法(Subcritical Water Extraction)で抽出されることができる。亜臨界抽出は溶媒が臨界点を超えない状態で抽出溶媒として用いることで、溶媒として何を選択するかによって超臨界抽出と同じ性能を現すことができ、用いる溶媒の種類は特に限定されるものではないが、特に、本発明では溶媒として酒精または精製水を用いることができる。   In another embodiment according to the present invention, carrot seed oil can be extracted by a Subcritical Water Extraction method. Subcritical extraction can be used as an extraction solvent in a state where the solvent does not exceed the critical point, and can exhibit the same performance as supercritical extraction depending on what is selected as the solvent, and the type of solvent used is particularly limited However, in the present invention, alcohol or purified water can be used as a solvent.

本発明による他の実施形態で、ニンジン種子油はマイクロ波抽出法で抽出されることができる。マイクロ波抽出法は溶媒を減らしてエネルギーを最大限に節約しながら短時間内で目的とする成分を抽出することができる方法で、用いる溶媒の種類は特に限定されるものではないが、特に、本発明では溶媒として酒精または精製水を用いることができる。   In another embodiment according to the present invention, carrot seed oil can be extracted by a microwave extraction method. The microwave extraction method is a method that can extract the target component within a short time while reducing the solvent to the maximum while saving energy, and the type of the solvent to be used is not particularly limited, In the present invention, alcohol or purified water can be used as a solvent.

本発明による他の実施形態で、ニンジン種子油は超音波抽出法で抽出されることができる。超音波抽出法は抽出物の変性や損失なしに短時間内に効率的に有用成分を抽出することができる方法で、用いる溶媒の種類が特に限定されるものではないが、特に、本発明では溶媒として酒精または精製水を用いることができる。   In another embodiment according to the present invention, carrot seed oil can be extracted by an ultrasonic extraction method. The ultrasonic extraction method is a method capable of efficiently extracting useful components within a short time without denaturation or loss of the extract, and the type of solvent used is not particularly limited. Alcohol or purified water can be used as the solvent.

本発明の組成物は、組成物の形態によってニンジン種子油を組成物の総重量に対して0.01〜100重量%の量で含有することができる。   The composition of the present invention may contain carrot seed oil in an amount of 0.01 to 100% by weight based on the total weight of the composition, depending on the form of the composition.

また、本発明の組成物は錠剤、丸剤、丹剤、カプセル剤、顆粒剤、散剤、軟膏剤、ドリンク剤または注射剤などの形態で薬学組成物または食品組成物として製剤化することができる。   The composition of the present invention can be formulated as a pharmaceutical composition or a food composition in the form of tablets, pills, pills, capsules, granules, powders, ointments, drinks or injections. .

本発明は通常的な方法によってニンジン種子油抽出物を含有する薬学組成物を提供する。薬学製剤の製造において、活性成分を担体とともに混合または希釈したり、容器形態の担体内に封入させることが好ましい。担体が希釈剤として用いられる場合には、活性成分に対する担体、賦形剤または媒質(medium)で作用する固形、半固形または液状の物質であることができる。従って、製剤は錠剤、丸剤、粉剤、サシェ、エリキシル剤、懸濁液剤、乳剤、溶液剤、シロップ剤、エアゾール、軟質または硬質ゼラチンカプセル剤、滅菌注射剤、滅菌粉剤などの形態であることができる。   The present invention provides a pharmaceutical composition containing carrot seed oil extract by conventional methods. In the production of a pharmaceutical preparation, it is preferable to mix or dilute the active ingredient together with a carrier, or encapsulate it in a carrier in a container form. When a carrier is used as a diluent, it can be a solid, semi-solid or liquid material that acts in a carrier, excipient or medium for the active ingredient. Therefore, the preparation may be in the form of tablets, pills, powders, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injections, sterile powders, etc. it can.

好ましい担体、賦形剤及び希釈剤の例としては、ラクトース、デキストロース、スクロース、ソルビトール、マンニトール、ケイ酸カルシウム、セルロース、メチルセルロース、微晶質セルロース、ポリビニルピロリドン、水、ヒドロキシ安息香酸メチル、ヒドロキシ安息香酸プロピル、タルク、マグネシウムステアレート及び鉱物油を挙げることができる。製剤は充填剤、抗凝集剤、潤滑剤、湿潤剤、香料、乳化剤、防腐剤などをさらに含むことができる。本発明の組成物は哺乳動物に投与された後活性成分の迅速、持続または遅延された放出を提供することができるように、本技術分野において周知の方法を用いて製剤化されることができる。   Examples of preferred carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, hydroxybenzoic acid Mention may be made of propyl, talc, magnesium stearate and mineral oil. The formulation can further include fillers, anti-aggregating agents, lubricants, wetting agents, perfumes, emulsifiers, preservatives and the like. The compositions of the present invention can be formulated using methods well known in the art so that they can provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. .

本発明の薬学組成物は、経口、経皮、皮下、静脈、腹腔、筋肉、局所塗布、貼布及びイオントフォレシス(iontophoresis)を含む各種経路を通じて投与されることができ、その中で局所適用及び経口投与が好ましい。   The pharmaceutical composition of the present invention can be administered through various routes including oral, transdermal, subcutaneous, intravenous, peritoneal, muscle, topical application, patch and iontophoresis, in which topical application And oral administration is preferred.

人の場合、活性化合物は通常1日投与量は1〜100mg/kg体重、好ましくは5〜70mg/kg体重の範囲であることができ、1回または数回に分けて投与することができる。しかし、活性成分の実際の投与量は治療する疾患、投与経路、患者の年齢、性別、体重及び疾患の重篤度などの各種関連因子に照らして決まることに理解されるべきであり、それにより、上記投与量は如何なる方法でも本発明の範囲を限定するのではない。   In the case of humans, the active compound usually has a daily dosage in the range of 1-100 mg / kg body weight, preferably 5-70 mg / kg body weight, and can be administered in one or several divided doses. However, it should be understood that the actual dosage of the active ingredient will depend on various relevant factors such as the disease being treated, the route of administration, the patient's age, sex, weight and severity of the disease, thereby The above doses do not limit the scope of the present invention in any way.

また、本発明は通常の方法によってニンジン実抽出物を含有する食品組成物を提供する。   Moreover, this invention provides the food composition containing a carrot seed extract by a normal method.

本発明の食品組成物は液状または固体状態の剤形を有するが、剤形は特に限定されず、例えば、錠剤、顆粒剤、ドリンク剤、キャラメル、ダイエットバーなどに製剤化されることができる。各剤形の食品組成物は有効成分以外に当該分野において通常用いられる各種成分を剤形または使用目的によって当業者が困難なことなく適宜選定して配合することができ、他の原料と同時に適用する場合相乗効果が発生することができる。   The food composition of the present invention has a liquid or solid dosage form, but the dosage form is not particularly limited, and can be formulated into tablets, granules, drinks, caramel, diet bars, and the like. In addition to the active ingredients, each dosage form of the food composition can be appropriately selected and blended with various ingredients normally used in the field according to the dosage form or purpose of use without difficulty by those skilled in the art. In doing so, a synergistic effect can occur.

以下、本発明を下記の実施例及び試験例を通じて説明する。実施例及び試験例は本発明をより詳しく説明するためのものであって、本発明の範囲が下記の実施例の範囲に制限されるのではない。   Hereinafter, the present invention will be described through the following examples and test examples. Examples and test examples are for explaining the present invention in more detail, and the scope of the present invention is not limited to the scope of the following examples.

また、当該技術分野において通常の知識を有する者であれば誰でも本発明の技術思想の範疇を逸脱しないで、添付した特許請求の範囲内で多様な変形及び修正が可能であることは明白な事実である。   It is obvious that any person having ordinary knowledge in the technical field can make various modifications and corrections within the scope of the appended claims without departing from the scope of the technical idea of the present invention. It is a fact.

[実施例1]ニンジン種子油製造
ニンジン種子前処理
生ニンジンの実を収穫し、種子を分離してニンジン種子を得た。
ニンジン種子油の製造
食品用搾油機(DS−1500、ダサン食品産業機械、韓国)を常温で5分間利用して、上記のように得たニンジン種子からニンジン種子油を得た(収率0.5〜2%)。
[Example 1] Carrot seed oil production
Carrot seed pretreatment Raw carrot fruits were harvested and seeds were separated to obtain carrot seeds.
Production of carrot seed oil Carrot seed oil was obtained from carrot seeds obtained as described above using a food oil press (DS-1500, Dasan Food Industrial Machinery, Korea) for 5 minutes at room temperature. 5-2%).

このように得たニンジン種子油を下記の試験例で用いた。   The carrot seed oil thus obtained was used in the following test examples.

[試験例1]
<ニンジン種子油の脂肪酸及び脂質類分析結果>
実施例1で製造したニンジン種子油の脂肪酸及び脂質類分析結果は以下の通りである。
[Test Example 1]
<Results of analysis of fatty acids and lipids in carrot seed oil>
The analysis results of fatty acids and lipids of the carrot seed oil produced in Example 1 are as follows.

Figure 0006615200
Figure 0006615200

上記表1の結果のように、本発明によるニンジン種子油は脂肪酸及び脂質類が検出された。   As the results of Table 1 above, fatty acids and lipids were detected in the carrot seed oil according to the present invention.

[試験例2]前立腺肥大症関連の生活の質の評価アンケート(BPH QoL−K1)
前立腺肥大症関連の生活の質を評価するために、韓国では以下の項目についてアンケートを実施している(前立腺肥大関連の生活の質に対するアンケート開発:信頼度及び妥当性検証、大韓泌尿器科学会誌41巻1号2000年、35−46)。
[Test Example 2] Questionnaire for evaluation of quality of life related to benign prostatic hyperplasia (BPH QoL-K1)
In order to evaluate the quality of life related to benign prostatic hyperplasia, a questionnaire was conducted on the following items in Korea (Development of a questionnaire on quality of life related to benign prostatic hyperplasia: Reliability and validity verification, Journal of Korean Urological Association 41 Volume 1, 2000, 35-46).

(1)普段頻繁に小便がしたくて不便である。
(2)夜寝ている間に頻繁に起きて小便をしなければならないため不便である。
(3)小便をした後にも小便が落ちて下着を濡らすことが不便である。
(4)気持ちは焦るが、小便が早く出なくて不便である。
(5)小便をしてもすっきりしなくて不便である。
(6)小便を我慢しにくくて不便である。
(7)小便の線が細くて不便である。
(8)体が疲れた時小便がよく出なくて不便である。
(9)生殖器部位が重くて凝る感じで不便である。
(10)小便をした後にも下腹が重くてビリッとした感じで不便である。
(1) I usually want to urinate frequently, which is inconvenient.
(2) It is inconvenient because you have to get up frequently and urinate while sleeping at night.
(3) It is inconvenient for the urine to fall and wet the underwear after urine.
(4) Feeling irritated but inconvenient because urine does not come out quickly.
(5) Even if urine is pissed, it is not clean and inconvenient.
(6) It is inconvenient because it is difficult to put up with urine.
(7) The urine line is thin and inconvenient.
(8) When the body gets tired, urination does not occur well, which is inconvenient.
(9) The genital area is heavy and inconvenient.
(10) Even after pissing, the lower abdomen is heavy and inconvenient because it feels crisp.

(11)頻繁に小便をするのが心配で飲み物を飲まなくなる。
(12)頻繁に小便をするため仕事に邪魔になる。
(13)長距離旅行をする時頻繁に小便がしたくて不便である。
(14)酒席で他人より頻繁にトイレに行くことが不便である。
(15)山登りをしたり野外活動をすることが不便である。
(16)小便を頻繁にするため外出する際に気になる。
(17)長時間車に乗るのが不安で緊張する。
(18)深い眠りに入りにくい。
(19)何事にも積極的でなく意欲がない。
(20)ひとつの仕事に集中しにくい。
(11) I'm worried about frequent urination and can't drink.
(12) Frequent urination is an obstacle to work.
(13) It is inconvenient to frequently urinate when traveling long distances.
(14) It is inconvenient to go to the toilet more frequently than others at liquor seats.
(15) It is inconvenient to climb a mountain or do outdoor activities.
(16) I'm worried about going out for frequent urination.
(17) I feel nervous about getting in the car for a long time.
(18) It is difficult to go into deep sleep.
(19) Nothing is aggressive or motivated.
(20) It is difficult to concentrate on one job.

(21)特別な理由もなく神経を高ぶらせる方である。
(22)無性に何事にも心配をしたり心配が多い。
(23)頻繁に小便がしたくて教会、お寺に行くなどの宗教活動をすることが難しい。
(24)集まりなどに参加して他人と付き合うことが気になる。
(25)老後に元気な生活を暮すことができるか自信がない。
(26)自分の健康状態に対する心配が多い。
(27)年をとるほど状態がより悪化し、治療をし続けるかどうか心配になる。
(28)自分の病気が悪性になるのではないかと心配になる。
(29)今後病症がさらに悪化すれば全く小便をすることができないのではないかと心配になる。
(30)性欲が以前に比べて減少した。
(21) The person who raises the nerve without any special reason.
(22) There are many worries and worries about anything.
(23) Frequent urination is difficult and it is difficult to do religious activities such as going to churches and temples.
(24) I'm interested in participating in gatherings and other people.
(25) I am not confident that I can live a healthy life after retirement.
(26) I have a lot of concerns about my health.
(27) The condition gets worse as he gets older, and he is worried about whether to continue treatment.
(28) I am worried that my illness will be malignant.
(29) I'm worried that if the disease gets worse in the future, I can't piss at all.
(30) Libido decreased compared to before.

(31)勃起がうまくできない。
(32)勃起ができてもすぐに萎えたり精液が快く排出されない。
(33)性的に何か不足で自信がない。
(34)よく疲れを感じる。
(35)体に気力が萎えて思い通りに活動することが大変である。
(31) The erection is not successful.
(32) Even if an erection occurs, it quickly wilts and semen is not discharged easily.
(33) I am not confident because of some lack of sex.
(34) I feel tired well.
(35) It is difficult to act as desired because the body is weak.

上記35種項目を「0:全然不便ではない。1:ほとんど不便ではない。2:耐える程度である。3:不便である。4:非常に不便である。5:耐えることができない。」にあたる点数でチェックをして総点を合わせて前立腺肥大症関連の生活の質を評価する。   The above 35 kinds of items correspond to “0: not at all inconvenient. 1: almost inconvenient. 2: tolerable. 3: inconvenient. 4: very inconvenient. 5: unable to withstand.” Check the score and combine the total score to assess the quality of life associated with benign prostatic hyperplasia.

普段小便に不便を感じる40代以上の男性60名を対象として初めてのアンケートを診断アンケートとして作成させ、その後、上記60名を20名ずつ三つの群に分けた。この中の一つの群に対しては、上記実施例1のニンジン種子油を1mlずつ分画可能なスポイド容器に盛って牛乳に28回含有させて摂取するようにした。即ち、標準化したニンジン種子油を1日1回28mlずつ摂取するようにした(ニンジン種子油摂取群)。他の一つの群に対しては、比較のためにラウリン酸を摂取するようにした。具体的には、大豆油1mlにラウリン酸2.5mgを溶かしてラウリン酸が溶解された大豆油を1日1回28ml(即ち、ラウリン酸の総含有量70mg、ニンジン種子油28mlに含有されたラウリン酸の量と同一)ずつ摂取するようにした(ラウリン酸摂取群)。また他の一つの群に対しては他の有効成分が含まれない大豆油を1日1回28mlずつ摂取するようにした(未摂取群)。このように約4週間摂取するようにした後、再び診断アンケートを作成するようにして、ニンジン種子油、ラウリン酸または大豆油の摂取前と後を比較した。
結果は診断アンケート評価点数の変化で表2に示す(N=60)。
The first questionnaire was created as a diagnostic questionnaire for 60 men in their 40s who usually feel inconvenient for urine, and then the 60 were divided into three groups of 20 each. For one of these groups, the carrot seed oil of Example 1 was placed in a spoid container capable of fractionating 1 ml at a time and contained in the milk 28 times. That is, 28 ml of standardized carrot seed oil was taken once a day (carrot seed oil intake group). For the other group, lauric acid was taken for comparison. Specifically, 2.5 mg of lauric acid was dissolved in 1 ml of soybean oil, and 28 ml of soybean oil dissolved in lauric acid was contained once a day (that is, the total content of lauric acid was 70 mg and carrot seed oil was contained in 28 ml of carrot seed oil). (Same as the amount of lauric acid). In addition, for one other group, 28 ml of soybean oil containing no other active ingredient was taken once a day (non-intake group). After ingesting for about 4 weeks in this way, a diagnostic questionnaire was prepared again to compare before and after ingestion of carrot seed oil, lauric acid or soybean oil.
The results are shown in Table 2 in terms of changes in the diagnostic questionnaire evaluation score (N = 60).

Figure 0006615200
Figure 0006615200

上記表2に表すように、ニンジン種子油を摂取した被験者たちの診断アンケート評価点数がより低かった。これは前立腺平滑筋弛緩によって前立腺肥大症状を緩和させて、前立腺の健康に良いと知られているラウリン酸を摂取した場合に比べて、改善程度が顕著に大きいことが分かる。従って、これを通じてニンジン種子油の摂取により前立腺肥大症症状が改善されることを確認することができる。   As shown in Table 2 above, the diagnostic questionnaire scores of subjects who took carrot seed oil were lower. This shows that the degree of improvement is remarkably greater than when lauric acid, which is known to be good for the health of the prostate, is relaxed by the relaxation of the prostate smooth muscle and the symptoms of prostatic hypertrophy are alleviated. Therefore, it can be confirmed that the symptoms of benign prostatic hyperplasia are improved by taking carrot seed oil.

以下で、本発明の一実施例による組成物の剤形例を説明するが、他の様々な剤形でも応用可能であり、これは本発明を限定するのではなく具体的に説明するためのものである。   Hereinafter, exemplary dosage forms of the composition according to an embodiment of the present invention will be described. However, various other dosage forms can be applied, which is not intended to limit the present invention but to specifically illustrate the present invention. Is.

[剤形例1]ニンジン種子油100%エキス
実施例1のニンジン種子油の製造時に固形分の含有量が20%以上になるように濃縮して、低温で熟成した後、液状形態の100%エキス製品を製造した。
[Formulation Example 1] Carrot Seed Oil 100% Extract After the carrot seed oil of Example 1 is produced, the carrot seed oil is concentrated so that the solid content is 20% or more, ripened at low temperature, and then 100% in liquid form. An extract product was produced.

[剤形例2]軟質カプセル剤
実施例1のニンジン種子油110mg、パーム油0.8mg、植物性硬化油0.48mg、黄蝋2.4mg及びレシチン3.6mgを混合し、通常の方法によって充填して軟質カプセルを製造した。
[Dosage Form Example 2] Soft capsule 110 mg of carrot seed oil of Example 1, 0.8 mg of palm oil, 0.48 mg of vegetable hardened oil, 2.4 mg of yellow wax and 3.6 mg of lecithin are mixed and mixed in a usual manner. Filled to produce soft capsules.

[剤形例3]錠剤
実施例1のニンジン種子油160mg、葡萄糖200mg及びデキストリン196mgを混合し、流動層乾燥器を利用して顆粒した後、シュガーエステル(sugar ester)7mgを添加して打錠機で打錠して錠剤を製造した。
[Formulation Example 3] Tablet 160 mg of carrot seed oil of Example 1, 200 mg of sucrose and 196 mg of dextrin are mixed, granulated using a fluid bed dryer, and then 7 mg of sugar ester is added to make a tablet. Tablets were produced by tableting with a machine.

[剤形例4]丸の製造
実施例1のニンジン種子油0.9g、糖0.3g、澱粉1.91g及びグリセリン0.56gを混合し、製丸機を利用して丸を製造した。
[Dosage Form Example 4] Production of Maru 0.9 g of carrot seed oil of Example 1, 0.3 g of sugar, 1.91 g of starch and 0.56 g of glycerin were mixed, and a circle was produced using a round machine.

[製造例5]顆粒剤
実施例1のニンジン種子油160mg、葡萄糖200mg及びデキストリン196mgを混合し、流動層乾燥器を利用して顆粒した後、包に充填して顆粒剤を製造した。
[Production Example 5] Granules 160 mg of carrot seed oil of Example 1, 200 mg of sucrose and 196 mg of dextrin were mixed, granulated using a fluid bed dryer, and then filled into a sachet to produce granules.

[製造例6]ドリンク剤
実施例1のニンジン種子油110mg、葡萄糖10g及びクエン酸2gを混合した後、精製水188gを加えて各瓶に200mlずつ充填した。瓶に充填した後、90℃で2〜3時間殺菌して飲み物を製造した。
[Production Example 6] Drink agent After mixing 110 mg of carrot seed oil of Example 1, 10 g of sucrose, and 2 g of citric acid, 188 g of purified water was added and 200 ml of each bottle was filled. After filling the bottle, it was sterilized at 90 ° C. for 2 to 3 hours to produce a drink.

Claims (4)

ニンジンの種子を搾油して得られたニンジン種子油を有効成分として含有する前立腺肥大症の予防及び治療用の組成物。 A composition for prevention and treatment of benign prostatic hyperplasia containing carrot seed oil obtained by squeezing carrot seeds as an active ingredient. 前記組成物はニンジン種子油を組成物の総重量に対して0.01〜100重量%の量で含有することを特徴とする請求項1に記載の前立腺肥大症の予防及び治療用の組成物。   The composition for preventing and treating prostatic hypertrophy according to claim 1, wherein the composition contains carrot seed oil in an amount of 0.01 to 100% by weight based on the total weight of the composition. . 前記組成物は、薬学組成物又は食品組成物として製剤化されていることを特徴とする請求項1又は2に記載の前立腺肥大症の予防及び治療用の組成物。 The composition for preventing and treating prostatic hypertrophy according to claim 1 or 2, wherein the composition is formulated as a pharmaceutical composition or a food composition. ニンジンの種子を搾油して得られたニンジン種子油を有効成分として含有する組成物を製剤化した前立腺肥大症の予防及び治療用の製剤。A preparation for the prevention and treatment of benign prostatic hyperplasia comprising a composition containing carrot seed oil obtained by squeezing carrot seeds as an active ingredient.
JP2017523344A 2014-10-31 2015-10-23 Composition for prevention and treatment of benign prostatic hyperplasia containing carrot seed oil, and formulation obtained by formulating the composition Active JP6615200B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2014-0149716 2014-10-31
KR1020140149716A KR102273967B1 (en) 2014-10-31 2014-10-31 Composition for preventing and treating prostatic hypertrophy containing ginseng seed oil
PCT/KR2015/011246 WO2016068547A1 (en) 2014-10-31 2015-10-23 Composition containing ginseng seed oil for prevention and treatment of prostatic hypertrophy

Publications (2)

Publication Number Publication Date
JP2018500285A JP2018500285A (en) 2018-01-11
JP6615200B2 true JP6615200B2 (en) 2019-12-04

Family

ID=55857807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017523344A Active JP6615200B2 (en) 2014-10-31 2015-10-23 Composition for prevention and treatment of benign prostatic hyperplasia containing carrot seed oil, and formulation obtained by formulating the composition

Country Status (4)

Country Link
JP (1) JP6615200B2 (en)
KR (1) KR102273967B1 (en)
CN (1) CN106999524B (en)
WO (1) WO2016068547A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210121892A (en) * 2020-03-31 2021-10-08 (주)아모레퍼시픽 Composition comprising ginseng seed oil

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23256A1 (en) * 2003-03-20 2008-01-24 Dalmer Lab Sa EXTRACT OBTAINED FROM ROYSTONEA REGIA FRUITS USED AGAINST PROSTATE HYPERPLASIA AND PROSTATITIS
CN101134054A (en) * 2006-08-30 2008-03-05 北京欧纳尔生物工程技术有限公司 Pharmaceutical composition for improving urination disorders caused by BPH and method for making the same
JP5628797B2 (en) * 2008-06-13 2014-11-19 アモーレパシフィック コーポレイションAmorepacific Corporation Skin external preparation composition containing ginseng flower or ginseng seed extract
KR101280300B1 (en) * 2011-05-04 2013-07-01 이현기 Health-aid food used the ginseng seed oil by main raw material
KR101790131B1 (en) * 2011-09-16 2017-10-25 초임계연구소 주식회사 Process for Preparing Ginseng seed Oil of High Oxidative Stability and Low Color with Supercritical Fluid
KR101429820B1 (en) * 2012-10-31 2014-08-12 세명대학교 산학협력단 Extract of ginseng seed, composition or oil having the same, and preparing method thereof
KR101452320B1 (en) * 2014-03-11 2014-10-22 주식회사 벤스랩 FERMENTED CAMELLIA JAPONICA SEED OIL INHIBITING 5-α REDUCTASE FOR IMPROVEMENT OF BENIGN PROSTATIC HYPERPLASIA AND ALOPECIA

Also Published As

Publication number Publication date
KR20160052001A (en) 2016-05-12
CN106999524A (en) 2017-08-01
KR102273967B1 (en) 2021-07-08
WO2016068547A1 (en) 2016-05-06
CN106999524B (en) 2021-01-15
JP2018500285A (en) 2018-01-11

Similar Documents

Publication Publication Date Title
JP2020172523A (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
CN108348565A (en) A kind of composition for preventing and treating muscle disease or improving muscle function containing Radix Platycodonis extract
CN108697685A (en) Containing moracin, Phellinus copper G or the root bark of white mulberry, the prevention of muscle disease and treatment is used or muscular function improvement composition
JP2022009308A (en) Composition for ameliorating climacteric symptoms or osteoporosis
TW201803582A (en) Nourishing tonic
CN101658641A (en) Health-care preparation containing gastrodia tuer, folium cortex eucommiae, and Ilex latifolia thumb and preparation method thereof
CN105412277A (en) Traditional Chinese medicinal composition of lipid-lowering tea and application of traditional Chinese medicinal composition
JP6615200B2 (en) Composition for prevention and treatment of benign prostatic hyperplasia containing carrot seed oil, and formulation obtained by formulating the composition
JP2011246417A (en) Skin beautifying soap
JP2004075584A (en) Therapeutic or prophylactic agent for vascular fibrosis
KR20210002037A (en) A composition for preventing, improving or treating pain comprising olive leaf and citrus pericarp extract
JP2018506524A (en) Composition for prevention, amelioration or treatment of burnout syndrome
KR101511364B1 (en) Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract
KR101910013B1 (en) A composition for improving, preventing and treating of pain comprising herb extract
KR20170100100A (en) A pharmaceutical composition comrprising Morus alba Linne extract for preventing or treating benign prostatic hyperplasia
KR102275268B1 (en) Composition for relieving menopausal symptom or osteoporosis
KR20160070912A (en) A composition for the prevention or treatment of abnormal weight loss comprising Citrus Unshiu Peel extract
CN107898947A (en) A kind of herb composition for treating gout, hyperuricemia and its preparation method and application
US10806766B2 (en) Method for treating, preventing, or alleviating osteoporosis
JP2004323439A (en) Composition for ameliorating blood viscosity
CN101816708B (en) Chinese medicinal composition for curing rheumatism and preparation method thereof
JP2016079124A (en) Swelling inhibitor or improver
KR20210003999A (en) Composition for preventing or treating rheumatoid arthritis comprising venom derived from Agkistrodon piscivorous piscivorous
CN104474337A (en) Preparation method of Chinese patent health granule containing green tea extract
JP6378926B2 (en) Composition for lowering blood glucose level

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191105

R150 Certificate of patent or registration of utility model

Ref document number: 6615200

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250